Genotype-based risk and pharmacogenetic sampling in clinical trials.
Schork
Nicholas J
NJ
Scripps Translational Science Institute and Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA. nschork@scripps.edu
Topol
Eric J
EJ
D000544:Alzheimer Disease / Q000188:drug therapy / Q000235:genetics; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D003627:Data Interpretation, Statistical; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D055106:Genome-Wide Association Study / Q000706:statistics & numerical data; D006331:Heart Diseases / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy / Q000235:genetics; D008297:Male; D015233:Models, Statistical; D009765:Obesity / Q000188:drug therapy / Q000235:genetics; D010597:Pharmacogenetics / Q000706:statistics & numerical data*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics; D018570:Risk Assessment; D012307:Risk Factors; D018401:Sample Size; D016896:Treatment Outcome